FOLLOW-UP OF PATIENTS WITH HAIRY CELL LEUKEMIA AFTER TREATMENT WITH CLADRIBINE
Abstract
Background. The long-term outcome in 16 patients with hairy cell leukemia (HCL) treated with cladribine between 1995 and 2003 is reported.
Patients and methods. Cladribine was administered to 13 patients in a dose 0.1 mg/kg/day for 7 days, and the same daily dose was applied once a week for 6 weeks in 3 patients. Their mean age was 57 years (range 32–67) and the male to female ratio 8:1. Four patients had also received a prior therapy with interferon and one was splenectomised.
Results. Complete remission (CR) was achieved in 12 (75%) patients and partial remission (PR) in 4 (25%) of cases. With a follow up of 9 years in 12 patients CR lasted between 18 and 88 months (mean 68), 3 (25%) of them relapsed after 54–80 months (mean 71) while 4 patients with PR progressed after 40 to76 months (mean 63). Six patients had an infection prior to or during the treatment.
Conclusions. In HCL patients cladribine treatment yields high percentage of CR and durable response, tolerable toxicity and prolonged survival.
Downloads
References
Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: A clinical review of 71 cases. Ann Intern Med 1978; 89: 677–86.
Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remission in hairy-cell leukemia induced by single infusion of 2-chlorodeoxyadenosine. New Engl J Med 1990; 322: 1117–21.
Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine: Respons, toxicity and long-term follow-up. J Clin Oncol 1997; 15: 1138–46.
Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918–26.
Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW. Increase incidence of second neoplasms in patients treated with interferon alfa-2b for hairy cell leukemia: A clinicopathologic assessment. Blood; 1994; 83: 2931–7.
Chubar Y, Bennett M. Cutaneous reaction in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. Brit J Haematol 2003; 122: 768–70.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
